NCT05599386 is a clinical trial of Preoperative test in Lung Cancer, sponsored by Jannie Bisgaard Stæhr.

Who is sponsoring NCT05599386?

NCT05599386 is sponsored by Jannie Bisgaard Stæhr.

What drugs are being tested in NCT05599386?

Interventions in NCT05599386: Preoperative test.

What condition does NCT05599386 study?

NCT05599386 studies Lung Cancer.

Is NCT05599386 still recruiting?

NCT05599386 is currently status unknown. Last updated 8 December 2023.

Last reviewed 2023-12-08 · How we verify

NCT05599386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictors of Acute and Persistent Postoperative Pain in Lung Cancer Surgery

Status unknown Last updated 8 December 2023

What this trial tests

trial testing Preoperative test in Lung Cancer in 100 participants. Status unknown.

Timeline

1 November 2022

Primary endpoint
6 August 2023

6 August 2024

Quick facts

Lead sponsor	Jannie Bisgaard Stæhr
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 November 2022
Primary completion	6 August 2023
Estimated completion	6 August 2024
Sites	1 location across Denmark

Drugs / interventions tested

Preoperative test

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Jannie Bisgaard Stæhr

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this observational study is to investigate if preoperative quantitative sensory testing, anxiety and depression symptoms, and biological markers are associated with the risk of developing acute and chronic postoperative pain after video-assisted Thoracoscopic surgery (VATS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Jannie Bisgaard Stæhr trials

Trials by the same sponsor.

NCT05038007 — Pain After Lung Cancer Surgery - Comparing Traditional Versus Prolonged Release Nerve Blockades · Phase 2 · unknown
NCT04633850 — Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05599386 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jannie Bisgaard Stæhr
Last refreshed: 8 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05599386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing